Charles Schwab Investment Management Inc. Boosts Position in Greenwich LifeSciences, Inc. $GLSI

Charles Schwab Investment Management Inc. raised its stake in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 15.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,007 shares of the company’s stock after buying an additional 2,552 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.14% of Greenwich LifeSciences worth $181,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Wells Fargo & Company MN grew its holdings in Greenwich LifeSciences by 54.8% during the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after buying an additional 1,008 shares in the last quarter. Bank of America Corp DE boosted its stake in Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after buying an additional 1,322 shares during the period. Rhumbline Advisers boosted its stake in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after buying an additional 3,168 shares during the period. Barclays PLC boosted its stake in Greenwich LifeSciences by 12.7% during the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after buying an additional 1,088 shares during the period. Finally, GAMMA Investing LLC bought a new stake in Greenwich LifeSciences during the first quarter valued at $126,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Price Performance

Shares of GLSI opened at $10.97 on Friday. The firm has a market cap of $149.52 million, a P/E ratio of -8.07 and a beta of 1.66. The stock has a 50 day simple moving average of $11.26 and a two-hundred day simple moving average of $10.54. Greenwich LifeSciences, Inc. has a 1 year low of $8.06 and a 1 year high of $16.50.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.06). On average, equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Analyst Ratings Changes

Separately, Noble Financial assumed coverage on Greenwich LifeSciences in a research note on Wednesday, August 20th. They set an “outperform” rating and a $45.00 price objective for the company. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $42.00.

Greenwich LifeSciences Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.